BioLargo Grew 2022 Revenue by More Than 125% Over the Prior Year

WESTMINSTER, CA / ACCESSWIRE / January 9, 2023 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its top-line revenue for 2022 exceeded $5.75 million, more than a 125% increase over its 2021 revenues. Note however, these figures are preliminary and are subject to change pending review and audit by the company's independent registered public accounting firm; the company will include its full results of operations in its annual report filed with the Securities and Exchange Commission on Form 10-K.

BioLargo CEO Dennis P. Calvert commented, "Our current success reflects the significance of our expanding portfolio of sustainable technologies and products. We believe our revenue growth will continue in 2023 as we focus on our PFAS removal water treatment system the AEC, the pet-odor product Pooph, and major engineering projects. This commercial success also validates our business model and raises the profile for our entire portfolio."

Calvert continued, "In our water technology business, we are finalizing our national network of channel partners and manufacturer's representatives for our PFAS and water treatment technologies, with nine signed agreements covering most of the United States and Canada. Our medical subsidiary also has secured agreements that mobilize over 25 manufacturer's representatives, and is in negotiations with a number of major channel partners that serve specific markets within the healthcare industry. All the initiatives we began in 2022 are moving forward and we look forward to sharing more information as it comes available. 2023 is shaping up to build off the success of 2022, and much more."

To learn more about how BioLargo's technologies help solve some of the world's toughest challenges, read the company's New Year's blog post, found here: https://biolargo.blogspot.com/2023/01/happy-new-year-from-biolargo.html

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") anticipated revenue and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.